Chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) is a protein that binds and blocks the C5a receptor (C5aR) and formylated peptide receptor, thereby inhibiting the immune cell recruitment associated with inflammation. If CHIPS was less reactive with existing human antibodies, it would be a promising anti-inflammatory drug candidate. Therefore, we applied directed evolution and computational/rational design to the CHIPS gene in order to generate new CHIPS variants displaying lower interaction with human IgG, yet retaining biological function. The optimization was performed in four rounds: one round of random mutagenesis to add diversity into the CHIPS gene and three rounds of DNA recombination by Fragment INduced Diversity (FIND w ). Every round was screened by phage selection and/or ELISA for decreased interaction with human IgG and retained C5aR binding. The mean binding of human anti-CHIPS IgG decreased with every round of evolution. For further optimization, new amino acid substitutions were introduced by rational design, based on the mutations identified during directed evolution. Finally, seven CHIPS variants with low interaction with human IgG and retained C5aR blocking capacity could be identified.
Introduction
Inflammation is the tissue response to injury or infection by pathogens. The attraction of immune cells and soluble molecules to the site of damage or infection initiates the healing process. Even though the ability to raise an inflammatory response is crucial for survival, the ability to control inflammation is also necessary for health. Anti-inflammatory drugs aim at blocking key events in inflammation for treatment of disorders with excessive or uncontrolled inflammation. Examples of such drugs are Remicade w and Kineret w , approved for treatment of rheumatoid arthritis.
Many bacteria have evolved strategies to evade the human immune system, for example, by avoiding recognition or by secreting proteins that neutralize the antibacterial effects mediated by the immune system. Chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) is a 14.1 kDa protein which is a potent inhibitor of immune cell recruitment and activation associated with inflammation, through binding and blocking the C5a receptor (C5aR) and the formylated peptide receptor Postma et al., 2004) . This way, CHIPS is a promising antiinflammatory protein for treatment of several inflammatory diseases, e.g. sepsis (Rittirsch et al., 2008) or ischemiareperfusion injury and immune complex disease (Heller et al., 1999) . However, most individuals have pre-formed titers of antibodies specific for CHIPS (Wright et al., 2007) . These antibodies might neutralize the function of CHIPS or induce an immune reaction, and hence the CHIPS molecule requires optimization to function well as a drug in the human circulation.
Directed evolution is an established approach for improving proteins. It has been utilized to improve many protein functions such as stability, activity or affinity (Johannes and Zhao, 2006) . Importantly for the development of protein therapeutics, directed evolution has proven to be a useful tool for generating protein variants with enhanced therapeutic potential (Yuan et al., 2005) . The directed evolution approach is particularly efficient as it does not require prior knowledge of the structure of the protein. Instead of using inefficient and time-consuming methods based on sitedirected mutagenesis, rounds of gene recombination and high-throughput screening can be performed to identify improved variants. The process can be repeated and beneficial mutations will be accumulated while mutations not required for the property of interest will be excluded, as reviewed by Yuan et al. (2005) and Zhao (2007) .
Several distinct methods for directed evolution have been described in the literature; among them DNA shuffling (Stemmer, 1994a (Stemmer, , 1994b and the Staggered Extension process (StEP) (Zhao et al., 1998; Yuan et al., 2005) . Another DNA recombination technology called Fragment INduced Diversity (FIND w ) has previously proven to be useful in the optimization of thermostability of carboxypeptidase U (Knecht et al., 2006) and the activity of IL-1 receptor antagonists (Dahlen et al., 2008) .
Even though directed evolution has been successfully utilized to identify new and improved protein variants, a drawback with this type of technology is the incapability of screening the entire sequence space of a protein. However, sequence space may be explored more efficiently if directed evolution is combined with computational tools and rational design (Wong et al., 2007; Zhao, 2007) .
In this study, FIND w was used in combination with rational/computational design of the CHIPS gene with the aim to create new protein variants with lower interaction with preexisting specific human IgG. An improved CHIPS molecule would be characterized by decreased reactivity with preexisting antibodies, but also preserved activity towards the C5aR. Therefore, receptor binding was monitored in parallel with the screening process for decreased IgG interaction.
When removing existing epitopes for human IgG, there is a risk for introducing new epitopes, which are important in the induction of a new antibody response. The truncated CHIPS molecule is a small protein of only 9.7 kDa, which is estimated to have a short half-life in the circulation. Therefore, the induction of a new antibody response will only be a potential issue if this molecule is going to be administered repeatedly to humans.
In conclusion, this study describes the isolation of new CHIPS variants with significantly reduced interaction with human anti-CHIPS IgG, yet retained C5aR blocking activity.
Materials and methods

Cloning, expression and purification of recombinant proteins
Wild-type (wt) CHIPS 1 -121 was cloned, expressed and purified as described earlier . CHIPS with truncated C-terminus (CHIPS DC) was 112 amino acids long with two additional non-relevant amino acids included in the C-terminal end of the expressed protein as a result of cloning (CHIPS 1 -112 ). Genes encoding CHIPS DC and its corresponding single mutants K61A, K69A and K100A as well as CHIPS DN/C (CHIPS 31 -113 ) were created from the gene encoding wt full-length CHIPS 1 -121 by truncation and sitedirected mutagenesis. These CHIPS variants were then cloned and expressed as described above. Single mutants were used for structural analysis by Haas et al. (2005) , but were also screened for anti-CHIPS IgG binding and mutants K61A, K69A and K100A showed decreased binding (data not shown).
CHIPS variants selected from libraries in this study were expressed in the same way, but purified from inclusion bodies (Gustafsson et al., 2009) or expressed by the Expressway Cell-Free E. coli Expression System (Invitrogen, Carlsbad, CA, USA) as recommended by the manufacturer.
Library construction
Random mutagenesis To create diverse libraries of CHIPS variants in Round 1 (Fig. 1) , two different methods of random mutagenesis were used to create in total four libraries. Error-prone PCR was performed as described previously (Leung et al., 1989) . One library with high mutation frequency (Library 1.1) and one with low mutation frequency (Library 1.2) were created. A 20 cycle PCR was performed using primers (Fw: 5 0 -TCGCGGCCCAGCCGGCCATGGCC TTTACTTTTGAACCG-3 0 and Rev: 5 0 -GCCTGCGGCCGC AGAT CTACCATTAATTACATAAG-3 0 ) in the presence of 7.5 mM MgCl 2 and 0.64 mM MnCl 2 . About 2.5 U AmpliTaq Thermostable DNA polymerase (Applied Biosystems, Foster City, CA, USA) was added and the reaction was performed using the program 948C, 5 min/(948C, 30 s/558C, 30 s/728C, 40 s) 20 times and finally elongation at 728C for 10 min. GeneMorph II (Stratagene, La Jolla, CA, USA) was used as recommended by the manufacturer. Ten picograms of DNA (a mixture of CHIPS DC and the corresponding K61A, K69A and K100A single mutants) were used for the design of the low mutation frequency library (Library 1.4) and 1 ng DNA for the library with higher mutation frequency (Library 1.3). The PCR reaction contained the primers described above and the PCR program was 958C, 2 min/(958C, 1 min/608C, 1 min and 728C, 1 min) 40 times and finally elongation at 728C for 10 min. To increase the mutation frequency in the 1 ng library, it was subjected to one more round of Genemorph II mutagenesis. This time, the amount of DNA in the PCR reaction was 10 ng. After purification, the PCR products were subcloned into the pGEM-T vector (Promega, Madison, WI, USA) according to the manufacturer's recommendations and the sequences were analyzed and base exchanges evaluated.
Fragment INduced Diversity
w FIND w recombinations were performed by the use of single-stranded DNA (ssDNA) and exonucleases and were utilized in Rounds 2 -4 to create diverse libraries of recombined clones (Fig. 1) . Briefly, ssDNA was prepared by generating PCR products using one biotinylated and one regular primer. The PCR product was immobilized on a column containing streptavidin-conjugated Fig. 1 . Experimental strategy to decrease CHIPS interaction with human anti-CHIPS IgG, yet retaining C5aR blocking activity. An initial round of random mutagenesis and phage selection/ELISA screening was followed by three rounds of FIND w and phage selection/ELISA screening for decreased IgG binding and retained C5aR peptide binding. Then, the structural distribution of the mutations in the improved clones was analyzed and new mutations were introduced by rational design. These clones were further analyzed for decreased IgG interaction and retained C5aR binding and inhibition.
magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and placed in the magnetic field of a mMACS separator. The PCR product was denatured with 0.1 M NaOH and the eluted non-biotinylated DNA strand was collected and purified by agarose gel electrophoresis using Recochips (Takara Bio. Inc., Shiga, Japan) according to the manufacturer's recommendations.
The FIND w experiments were initiated by fragmenting 200 ng sense and antisense ssDNA, respectively, with Exonuclease I (Exo I) (New England Biolabs, Ipswich, MA, USA) (100 U/mg DNA) for 10 min, Exonuclease V (Exo V) (USB, Cleveland, OH, USA) (25 U/mg DNA) for 45 min and Exonuclease VII (Exo VII) (USB) (5 U/mg DNA) for 30 min in separate tubes in buffers as recommended by the manufacturers. The ssDNA fragments resulting from the exonuclease digestions were recombined in a PCR-like reaction, without added primers, followed by amplification by a standard PCR protocol. After purification, PCR products were subcloned into the pGEM-T vector (Promega) according to the manufacturer's recommendations and sequences were analyzed.
In some cases, FIND w was performed with differences from the protocol described above. In FIND w Round 1, Library 2.1 was created with the aim to introduce more mutations in the C-terminal end of the protein (amino acids 110 -112). This was achieved by addition of a randomized oligonucleotide in 1:1 ratio with CHIPS in the primerless PCR step. The oligo was synthesized to contain 7.5% randomized substitutions, corresponding to approximately two amino acid changes per sequence (Sneeden and Loeb, 2003; Reetz, 2004) . Library 2.2 was created under error-prone conditions in order to introduce more mutations over the entire CHIPS sequence. Both the primerless PCR step and the subsequent PCR were performed under error-prone conditions as described previously (Leung et al., 1989) , in the presence of 7 mM MgCl 2 , 0.5 mM MnCl 2 and 1.25 U AmpliTaq Thermostable DNA polymerase (Applied Biosystems). Furthermore, the two libraries in FIND w Round 3 (Libraries 4.1 and 4.2) were designed by applying two FIND w reactions sequentially, without any selection or screening in between, with the aim to further increase the number of recombined clones.
Protein expression in plate format CHIPS libraries created by random mutagenesis or FIND w were cloned into a modified pRSET B vector (Invitrogen) in BbsI and BglII sites for expression in Escherichia coli. Libraries were transformed into E.coli BL21 star (DE3) pLysS (Invitrogen), plated on 20 cm Qtray plates with Luria Broth (LB) agar supplemented with 50 mg/ml ampicillin and 34 mg/ml chloramphenicol and incubated at 378C overnight. The following day, E.coli colonies were picked and inoculated in 96-well round bottom plates containing 150 ml LB supplemented with 50 mg/ml ampicillin and 34 mg/ml chloramphenicol using a colony picker robot. The cultures were incubated at 378C with 78% humidity and shaking at 700 rpm in a Multitron plate shaker (Infors HT, Bottmingen, Switzerland) overnight. Day cultures were prepared from the overnight cultures by 1/100 dilution into fresh medium with 50 mg/ml ampicillin and incubation was continued at 378C as above. To induce protein expression, 0.5 mM isopropyl b-D-thiogalactoside was added to the cultures after 3 h, and the cultures were then cultivated for another 3 h. Escherichia coli cultures were pelleted by centrifugation and pellets were frozen at 2208C. Lysates were prepared by freeze-thawing the E.coli pellet in PBS 0.05% Tween 20 with Complete EDTA-free protease inhibitor (Roche, Basel, Switzerland), 25 U/ml Benzonase (SigmaAldrich, St Louis, MO, USA) and 1 kU/ml rLysozyme (EMD Chemicals, Darmstadt, Germany) and incubation for 10 min at room temperature (RT) with shaking.
Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange II mutagenesis kit (Stratagene) according to the manufacturer's recommendations with primers carrying the specific mutation. The new CHIPS variants were sequence verified and transformed into E.coli BL21 Star(DE3)pLysS (Invitrogen) for protein expression.
Affinity purification of human anti-CHIPS 31 -113 IgG
Purified CHIPS 31 -113 was coupled to CNBr-activated Sepharose 4B (Amersham Biosciences, Uppsala, Sweden) and packed on a Tricon 5/20 column (Amersham Biosciences) according to the manufacturer's instructions. Affinity purification was performed on an Ä KTA Prime system (Amersham Biosciences) according to the manufacturer's protocol. Total human IgG (1 g) (IV-IgG) (Sanquin, Amsterdam, The Netherlands) was run over the column and bound human IgG was eluted with 0.1 M glycine pH 3.0 and the pH neutralized with 1 M Tris, pH 8.0. Eluted fractions containing protein were pooled and buffer was changed to PBS on PD-10 columns (Amersham Biosciences).
Phage selection
Random mutagenesis libraries and FIND w libraries were cloned into the SfiI and NotI sites of the phagemid pFAB75 (Johansen et al., 1995) and transformed into E.coli TOP10 F 0 (Invitrogen) for expression on phage particles. Phage stocks were prepared according to standard protocols, using VSCM13 (Stratagene) as a helper phage (Cicortas Gunnarsson et al., 2004) . Positive selections were performed on a biotinylated C5aR peptide with sulfated tyrosines, consisting of amino acids 7 -28 (biotin-C5aR peptide) (AnaSpec, San Jose, CA, USA) at a final concentration of 10 27 M and streptavidin-coated magnetic Dynabeads (Invitrogen). The mixture was incubated for 1 h on rotation at RT, followed by extensive washing in PBS 0.05% Tween 20 with 1% bovine serum albumin (BSA) (selection buffer). Elution of peptide binders was performed with 1 M Glycine 0.1% BSA, pH 2.2, followed by addition of 1 M Tris pH 9.0 to neutralize the eluate. The selection protocol was then repeated once as described above. Directly after the second round of positive selection, CHIPS phage stocks were subjected to a round of negative selection for human anti-CHIPS 312113 IgG binding. Estapor 0.83 mm magnetic beads (Bangs-Laboratories Inc., Fishers, IN, USA) coated with human anti-CHIPS 31 -113 IgG were washed three times in selection buffer and then blocked in selection buffer for 1 h on rotation at RT. The eluate from the positive selection was added to the beads, and they were incubated for another 15 min at RT. After separation on a magnet, the supernatant was saved and used for infection of exponentially growing E.coli TOP10 F 0 and phagemids were purified from the E.coli.
Enzyme-linked immunosorbent assay
ELISA was used for screening and characterization of binding throughout the study. Maxisorb clear or white 96-or 384-well plates (Nunc, Roskilde, Denmark) were coated overnight at 48C with the specific protein or antibody in PBS. Incubations were carried out in a volume of 100 or 25 ml for 1 h at RT if not described differently, always followed by washing three times with PBS 0.05% Tween 20. Super Signal ELISA Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) was used and luminescence was measured.
Analysis of protein expression For quantification of expressed proteins, plates were coated with 3 mg/ml monoclonal anti-CHIPS antibody 2H7 recognizing a peptide of CHIPS amino acids 24-30 . Plates were blocked in PBS 0.05% Tween 20 with 3% milk powder, washed and incubated with dilutions of lysates from the DC CHIPS variants. Binding was detected with 3 mg/ml polyclonal rabbit anti-CHIPS N-terminal IgG (IgG produced by immunization of a rabbit with a KLH-coupled synthetic peptide corresponding to CHIPS N-terminal amino acids 1 -14) and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Southern Biotech, Birmingham, AL, USA). 31 -113 IgG to CHIPS DC variants, plates were coated, blocked and incubated with E.coli lysates as described for analysis of protein expression. Affinity purified human anti-CHIPS 31 -113 IgG was added and binding was detected with goat-anti-human IgG HRP (Jackson ImmunoResearch, West Grove, PA, USA). During initial screenings, single-point measurements were performed on the CHIPS lysates and were compared with a titration curve of wt CHIPS 1 -121 . Results were correlated to those from the expression ELISA. Full titration curves were made for a limited number of variants in later screenings/ characterizations.
Analysis of anti-CHIPS IgG binding For detection of binding of human anti-CHIPS
Analysis of peptide binding In order to measure the binding of CHIPS variants toward the C5aR peptide, 5 mg/ml Streptavidin (Sigma-Aldrich) was coated. Furthermore, the biotin-C5aR peptide (Anaspec) was added to a final concentration of 0.3 mg/ml after washing and blocking the plates (2% BSA in PBS 0.05% Tween 20). Plates were then incubated with CHIPS lysates and detection was performed with 1 mg/ml mAb 2H7 and HRP-conjugated rabbit anti-mouse IgG (Dako, Glostrup, Denmark).
Analysis of anti-CHIPS IgG binding in competition with CHIPS 1 -121 Five-fold dilution series of the CHIPS variants were preincubated with 60 ng/ml affinity purified human anti-CHIPS 31 -113 polyclonal IgG in a polypropylene plate (Nunc) for 2 h at RT. Purified wt CHIPS 1 -121 was coated in the ELISA plate. After blocking with 4% BSA in PBS 0.05% Tween 20, the IgG/CHIPS variant mixtures were added to the plate and further incubated for 2 h at RT. Detection was performed with goat-anti-human IgG HRP and o-phenylenediamine dihydrochloride substrate.
Analysis of serum IgG binding IgG from human pooled serum was tested for reactivity with CHIPS variants in ELISA. The plate was coated with equimolar amounts of the proteins or PBS. After blocking in PBS 0.05% Tween 20 with 3% milk powder, serially diluted human serum was added. IgG binding to CHIPS variants was detected with rabbit anti-human IgG-HRP (Dako). The IgG titer reported was calculated by plotting the luminescence data against the dilution factor followed by analysis in a non-linear curve fitting model. The titer was reported as the dilution factor of serum at which a cut-off value was reached. This cut-off value was set by coating wt CHIPS 1 -121 and analyzing binding of IgG in pooled human serum of different dilutions. The signal generated by serum diluted 1/40 000 was set as a cut-off value, since IgG binding to CHIPS 1 -121 at this dilution was shown to be in the dynamic interval of the binding curve.
Biological assays
Binding to the human C5aR Human neutrophils were prepared from buffy coats obtained from Lund University Hospital (Lund, Sweden). The buffy coats were diluted 1/1 (v/v) with PBS with 2% newborn calf serum (NBS) (Lonza), and added on top of Ficoll Paque plus (GE Healthcare, Uppsala, Sweden). Neutrophils were collected in PBS after centrifugation at 1000g for 30 min. Then, erythrocytes were lysed by incubation with ice-cold H 2 O for 30 s and 4 Â PBS was added and the suspension was centrifuged at 600g 48C for 7 min. Neutrophils were collected in PBS with 2% NBS and remaining erythrocytes were lysed by incubation with ice-cold H 2 O for 30 s and 4 Â PBS was added. Neutrophils were collected by centrifugation at 1000g 48C for 5 min.
Binding to the human C5aR was studied on human neutrophils as well as on the stably transfected cell line U937/ C5aR, a generous gift from Dr E. Prossnitz (University of New Mexico, Albuquerque, NM, USA). Cells were grown in 75 cm 2 cell culture flasks in a 5% CO 2 incubator at 378C and were maintained in RPMI 1640 medium with L-glutamine (Lonza, Basel, Switzerland) and 10% fetal bovine serum (Lonza). Binding to the C5aR was analyzed in two ways by flow cytometry. In the first method, dilution series of DC CHIPS variants (expressed by the Expressway Cell-Free E.coli Expression System from Invitrogen) were incubated with cells and CHIPS binding was detected by the 2H7 monoclonal anti-CHIPS antibody, followed by an R-phycoerythrin (RPE)-labeled goat anti-mouse immunoglobulin (Dako). In the second method, CHIPS DC variants were incubated with cells as above, then the degree of inhibition of binding was quantified by adding a monoclonal anti-C5aR antibody and the RPE-labeled goat anti-mouse immunoglobulin to the cells.
C5aR blocking C5a-induced calcium mobilization in human neutrophils was studied by flow cytometry. A total of 5 Â 10 6 /ml neutrophils were incubated with 2 mM Fluo-3AM (Sigma-Aldrich) in RPMI 1640 medium with 0.05% BSA for 30 min at RT, followed by washing and resuspension in RPMI 1640 with 0.05% BSA. Cells were then preincubated with a 3-fold dilution series of purified CHIPS variants (re-cloned into the DN/C format) at RT for 30 min and C5a (Sigma-Aldrich) (final concentration 0.3 nM) was added to induce calcium release. This was measured by means of fluorescence on a FACScalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
C5a-induced migration of human neutrophils (chemotaxis) was measured in a transwell system (Neuro Probe, Gaithersburg, MD, USA). Therefore, 5 Â 10 6 /ml human neutrophils were labeled with 4 mM Calcein-AM (Sigma-Aldrich), washed in Hank's balanced salt solution (HBSS) with 1% human serum albumin (HSA) and resuspended in HBSS with 1% HSA. Cells were further incubated for 15 min at RT with a titration of purified CHIPS DN/C variants. C5a was added to the lower compartment of the wells to a final concentration of 1 nM. Labeled cells were added to the upper compartments. Plates were incubated for 30 min at 378C with 5% CO 2 . Then filters were rinsed with PBS to remove non-migrating cells and fluorescence was measured at an excitation of 485 nm and emission of 530 nm in a fluorescence plate reader. The data were fitted in a nonlinear regression model (sigmoidal dose -response curve 0 -100 with variable slope).
Thermal denaturation by circular dichroism spectroscopy
The circular dichroism (CD) signal at 212 nm was monitored during thermal unfolding of the CHIPS variants from 48C to 858C at a scan rate of 18C/min, response of 16 s and bandwidth of 1 nm. The protein concentration was 0.5 mg/ml in PBS pH 7.2 and a quartz cuvette with 1 mm pathlength was used. To investigate the reversibility, a thermal scan from 858C to 48C was monitored after the upward scan. Structural changes were determined from far-UV CD spectra, at 48C or 858C, before and after each thermal scan. Spectra were recorded between 250 and 195 nm; the scan rate was 20 nm/min, the response 8 s and the bandwidth 1 nm. All CD spectroscopy was carried out on a Jasco (Jasco Inc., Easton, MD, USA) J-720 spectropolarimeter with a JASCO PTC-343 Peltier type thermostated cell holder. Since the thermal unfolding was irreversible for all variants, no thermodynamic stability could be obtained. However, since unfolding was monitored at the same speed for all variants, the T m gives comparative thermal stabilities between the variants. The T m was obtained by fitting Eq. (1) to CD data.
In Eq. (1), 1 obs is the observed ellipticity at 212 nm, k N , b N , k U and b U define the baselines of the native and unfolded states, respectively. A is a parameter in the fitting process but has no value for an irreversible unfolding, T the temperature in kelvin and R the gas constant. In the equation, the protein is assumed to follow a two-state denaturation process and have a constant DC8 p in the temperature region, so that the denaturation follows the Gibbs -Helmholtz equation. For such an unfolding, the parameter A is DH8 and 3000 is an estimated measure for DC8 p , but these parameters have no relevance for an irreversible unfolding.
Molecular modeling
Modeling was performed by the use of the available CHIPS 312121 NMR structure (PDB code: 1XEE) and the PyMol molecular graphics program (DeLano, 2008) .
Results
Strategy to create CHIPS variants with low IgG binding
The evolution for decreased anti-CHIPS IgG interaction, yet preserved C5aR blocking activity was performed in one round of random mutagenesis and three rounds of FIND w recombinations, followed by computational analysis and rational design (Fig. 1) . A shorter CHIPS variant, truncated at both the N-and the C-termini (CHIPS DN/C), and single mutants K61A, K69A and K100A, previously shown to be less prone to bind human anti-CHIPS IgG (data not shown), were chosen as the starting material for the optimization process. The first 30 N-terminal amino acids in CHIPS were kept as a recognition sequence (which was not subjected to mutagenesis or recombinations) for capture antibodies in ELISA. Selected clones were then re-cloned into the truncated CHIPS DN/C format before characterization of biological activity (C5aR inhibition).
In order to increase the probability to find new CHIPS variants with decreased IgG binding, several different ELISAs were applied for studying the interaction between CHIPS and affinity purified anti-CHIPS 31 -113 IgG. Several screening rounds were performed in ELISA for each of the libraries in Rounds 1, 3 and 4. The primary screening of each round was performed by one-point measurements, whereas the assays were performed more comprehensively in later rounds of screening by making full titration curves for each of the selected mutants.
Furthermore, to preserve the biological functionality of the new CHIPS variants during selections and screening, binding to a peptide of the C5aR N-terminal amino acids 7 -28 with sulfated tyrosines was continuously monitored. Residues 10-18 of the C5aR have previously been shown to be the binding domain for CHIPS (Postma et al., 2005) . Tyrosines 11 and 14 of the C5aR have been shown to be sulfated, which was shown to be critical for C5a-dependent activation of the C5aR (Farzan et al., 2001) . A recent study on CHIPS binding to peptides of the C5aR N-terminus stresses the role for sulfated tyrosines in positions 11 and 14 for CHIPS binding and shows that CHIPS binds with high affinity to sulfated peptides of the C5aR N-terminus (Ippel et al., 2009 ).
Random mutagenesis libraries and screening
Diversity was introduced into the CHIPS DC sequence by random mutagenesis. Four libraries with different mutation frequencies were created (details of the libraries are described in Table I ). All four libraries were subjected to phage selection; first, for C5aR peptide binding ( positive selection), followed by selection for decreased anti-CHIPS IgG binding (negative selection). Supernatants from the negative selection were pooled, allowed to infect E.coli and phagemids were purified. The CHIPS encoding sequences from the pool of mutants were recloned into the expression vector pRSET B and 360 CHIPS variants were subsequently expressed in plate format and screened in ELISA for decreased anti-CHIPS 31 -113 IgG binding ( Fig. 2A) 
FIND libraries and screening
FIND
w round 1 Two libraries with different recombination frequencies (number of cross-overs) were created from the nine clones (containing in total 18 amino acid substitutions) selected in the random mutagenesis step (Table I ). Library 2.1 was designed by FIND w with a short randomized oligonucleotide added to the reaction. This oligonucleotide was corresponding to amino acids 100 -112 and was added to increase the number of mutations in the C-terminal end of CHIPS. Library 2.2 was designed by FIND w under errorprone conditions to increase the number of new mutations in the entire CHIPS sequence.
The libraries were subjected to phage selection as described above and supernatants from the negative selection were pooled, and phagemids were purified from E.coli. This pool of DNA was used as the starting material for the second round of FIND w .
w round 2 In the second round of FIND w , one library was created (Library 3.1) ( Table I) . A total of 6.3 Â 10 3 clones were expressed in plate format and screened in ELISA for both interaction with anti-CHIPS 31 -113 IgG and C5aR peptide. The average binding to the C5aR peptide was 92% of wt CHIPS 1 -121 binding.
The 320 clones that showed maximum 70% of wt CHIPS 1 -121 binding to the anti-CHIPS 31 -113 IgG and at least 80% of wt CHIPS 1 -121 binding to the C5aR peptide were selected for a second round of ELISA screening for lower anti-CHIPS 31 -113 IgG binding. The response was correlated to expression levels by analysis in a separate ELISA. The most improved clone showed 13% anti-CHIPS 31 -113 IgG binding when compared with wt CHIPS 1 -121 , and the average value among the clones was 39% binding (Fig. 2A) .
Of these, 40 clones showed ,40% binding compared with wt CHIPS 1 -121 and were then further analyzed in a dosedependent set-up in ELISA. The EC 50 value (i.e. the concentration of each CHIPS variant mediating half-maximal binding) and plateau value of each variant were determined and compared with the values of wt CHIPS 1 -121 . The 12 clones that were improved compared with the best clone from the random mutagenesis round were selected for a last round of FIND w recombination. These clones showed at least 2.4 higher EC 50 and maximum 54% of wt CHIPS 1 -121 plateau value in anti-CHIPS 31 -113 IgG binding. Table I) . Both libraries were designed by the use of two repeated rounds of FIND w without any selection or screening in between, which generated a higher frequency of recombined clones (92%) than in the previous libraries (Table I) .
A total of 9.6 Â 10 3 clones were expressed in plate format and screened in ELISA for decreased human anti-CHIPS 31 -113 IgG binding. One thousand clones showed maximum 10% of wt CHIPS 1 -121 binding to anti-CHIPS 31 -113 IgG and were further analyzed for C5aR peptide binding in ELISA. The mean value of C5aR peptide binding was 45% of wt CHIPS 1 -121 binding.
The 96 clones that showed at least 95% binding to the C5aR peptide when compared with wt CHIPS 1 -121 were selected for further analysis in ELISA for decreased anti-CHIPS 31 -113 IgG binding and in flow cytometry for retained C5aR binding. The clones showed on average 7.1% binding of anti-CHIPS 31 -113 IgG when compared with wt CHIPS 1 -121 . The most improved clone showed 2.5% binding when compared with wt CHIPS 1 -121 (Fig. 2B) . The distribution of the 96 clones is shown in Fig. 2C .
After sequencing, 42 unique clones were identified. All 42 clones showed ,10% binding to the anti-CHIPS 31 -113 IgG when compared with wt CHIPS 1 -121 after the last round of screening. These clones were expressed by a cell-free protein expression system to improve the yield of protein, and the products were characterized further by ELISA and flow cytometry. During this thorough characterization, a small number of clones showed higher binding toward the anti-CHIPS 31 -113 IgG than measured during the previous screening, and hence the cut-off value was set to 13% instead of the previous 10%. The 10 clones showing the highest binding to the human C5aR as well as low binding to anti-CHIPS 31 -113 IgG (,13% of wt CHIPS 1 -121 ) (Fig. 3) were selected for further mutagenesis. These clones are shown in Supplementary Table I available at PEDS online.
Molecular modeling and rational design
In an attempt to decrease the interaction with anti-CHIPS 31 -113 IgG even further, 27 new CHIPS variants were created by site-directed mutagenesis of four of the 10 selected clones (Supplementary Tables I and II available at PEDS online). By introducing new mutations into these specific clones, all 12 mutated positions identified during directed evolution were represented. The site-directed mutagenesis was designed by analyzing the protein structure, with special attention paid to the structural role of the mutated amino acid residues generated during the directed evolution. New substitutions were suggested in some of these mutated positions and these were also joined in new combinations compared with the clones generated during directed evolution.
Characterization of CHIPS variants
The mutants were first analyzed by ELISA for binding to the C5aR peptide. The clones that showed at least 90% binding to the peptide were selected for further analyses. 
Optimization of CHIPS by directed evolution
In subsequent binding experiments performed with human neutrophils, clone S3.09 with alanine in position 112 was found to display improved binding to the C5aR (105 of wt CHIPS 1 -121 binding) compared with the corresponding clone with valine in this position (F3.08; 84% of wt CHIPS 1 -121 binding). For this reason, V112 was substituted to an alanine in position 112 in most of the selected clones. In addition, the clones were recloned into the DN/C format and were subsequently purified from inclusion bodies through extensive washing of the inclusion bodies, solubilization, refolding (dropwise addition of the protein solution into PBS) and gel filtration as described previously (Gustafsson et al., 2009) . The 16 clones that showed the highest C5aR blocking activity (blocking of Ca 2þ release after C5a stimulation) in flow cytometry experiments on U937/C5aR cells were selected for further characterizations. After analyzing CHIPS binding to serum IgG by ELISA and biological functionality (C5aR blocking activity) by flow cytometry on human neutrophils, seven clones could finally be selected as the most promising candidates (Supplementary Table III available at PEDS online). This choice was based on the following criteria: serum IgG titer at maximum 2.3% and C5aR blocking activity (in neutrophils) of at least 50% of that observed for wt CHIPS 1 -121 . These clones were further characterized by studying inhibition of neutrophil migration (chemotaxis) and by determining T m values by CD spectroscopy (Table II) . The temperature denaturations show that all clones have a high melting temperature compared with CHIPS DN/C. Some variants show a minor transition at a low temperature and a major transition at a high temperature, indicating partial unfolding at the low temperature. CHIPS DN/C shows a reversible unfolding whereas all seven clones show an irreversible thermal unfolding. This suggests a higher aggregation propensity of the clones in the unfolded state compared with wt CHIPS 1 -121 and CHIPS DN/C. The theoretical pI values of the seven clones are given in Table II . These values are slightly higher than the pI of wt CHIPS 1 -121 (pI of 9.36), and hence wt CHIPS 1 -121 and the seven variants carry a net positive charge at a pH lower than 9.36. Figure 4A shows a sequence alignment of the top seven clones. The clones contain between five and eight mutations per sequence. Three mutated positions are located in the a-helix, one in the loop between the b 1 and b 2 strands, two in the loop between the b 2 and b 3 strands, one in b strand 3, one in the loop between the b 3 and b 4 strands and two in b strand 4. More specifically, positions K40, D42, N77, K100, N111 and G112 are mutated in four or more clones in different combinations with mutations in positions K50, K69, K92 and K105. Substitutions N77Y, N111K and G112A are most common among the clones, represented in six out of seven clones, respectively.
Out of the seven clones, one variant (376) was identified as the most interesting and will be further characterized in future studies. Figure 4B shows a surface representation of clone 376 with the mutations marked in green. Although this candidate does not have the lowest IgG titer among the top seven clones, it has a titer that is decreased almost 180 times compared with wt CHIPS 1 -121 . The highly preserved ability of this mutant to block C5aR signaling and inhibit C5a-induced chemotaxis was considered to be of greater importance.
Discussion
Although a certain characteristic of a protein can be of interest for drug development, other properties might need to be improved in order to design a promising drug candidate. Today, there are a number of drugs (approved or in clinical phase trials) that have been optimized by the use of protein engineering. Tissue plasminogen activator (tPA) has been improved several times to finally have a longer half-life in serum as well as higher specificity for fibrin (Keyt et al., 1994) . This engineered version of tPA (TNKase w ) is now approved for the treatment of acute myocardial infarction. ANYARA is a superantigen coupled antibody with tumor specificity, currently in clinical trials. The antigenicity of the superantigen staphylococcal enterotoxin A has been Data from one separate experiment, in which both wavelength and temperature were scanned.
E. Gustafsson et al. decreased to make ANYARA a more attractive anti-tumor drug candidate (Erlandsson et al., 2003) .
In combination with a well-designed screening method, directed evolution can be utilized to improve almost any characteristic of a protein, e.g. improved affinity, higher potency or decreased immunogenicity. However, when improving a specific property of interest, it is important to continuously monitor other significant characteristics of the protein that might be altered during the protein evolution.
In this study, we were able to decrease the interaction between CHIPS variants and human IgG to only 0.5% of wt CHIPS 1 -121 binding, while retaining C5aR blocking activity.
This was achieved by continuously monitoring C5aR binding during the rounds of directed evolution and screening to ensure that this property was not lost during the optimization process. Moreover, to increase the probability to find new CHIPS variants with decreased IgG binding, several methods for verifying this property were applied during the rounds of screening.
Directed evolution (random mutagenesis and FIND w ) was applied in combination with computational/rational design to improve the CHIPS molecule toward lower interaction with specific human IgG. Diversity was first introduced into the sequence by random mutagenesis, followed by three rounds of FIND w performed sequentially with selection and/or screening after each round. Without need for prior knowledge of the epitopes for pre-existing IgG in CHIPS, the mutations found to be beneficial in the previous round were recombined to form new CHIPS variants and IgG binding was shown to decrease with every round. After the last round of FIND w , the best clones displayed a binding of human anti-CHIPS 31 -113 IgG that was reduced to only 2.5% of the binding toward wt CHIPS 1 -121 . This was a significant decrease in binding achieved by the application of directed evolution. However, to decrease the binding even further, site-directed mutagenesis was designed by molecular modeling and additional mutations were introduced. The most improved final clone showed 0.5% of the IgG binding observed for wt CHIPS 1 -121 . This was accomplished by analyzing the structural distribution of the positions found to be of importance in the directed evolution process.
The combination of mutations in the top seven clones is responsible for the unique properties of these variants. In an attempt to investigate the contribution of the different mutated residues, a structural analysis of the most frequently mutated positions among the final seven clones, D42, N77, N111 and G112, was applied. D42 is an amino acid in the a-helix that seems to be important for intramolecular interactions. Substitution to a valine (V) potentially breaks the H-H bond formed between D42 and R46. This change may alter the structure of the CHIPS molecule and possibly also change an IgG epitope. The introduction of the hydrophobic valine at position 42 seems to increase the stability of the molecule. Most likely, this hydrophobic residue fits well into the interior of the structure and stabilizes the hydrophobic core and that may be the reason why it is represented in six out of the seven selected clones. However, the mutation might affect the reversibility and the aggregation propensity in the unfolded state due to increased hydrophobicity. N77 is mutated to a tyrosine (Y) in six of the clones and to a histidine (H) in one clone. It is exposed in the b2-b3 loop and could be directly involved in IgG binding. When comparing N77Y and N77H, it appears that the tyrosine increases the stability compared with the histidine in this position. On the other hand, clone 376, with a histidine in this position, has a better preserved biological function (inhibition of chemotaxis) when compared with clone 335 that is identical apart from a tyrosine in position 77. N111 is an exposed residue in b4. This position becomes more positively charged upon substitution to lysine (K), which is a significant change of the surface that was shown to be beneficial in six out of the seven clones. G112 in b4 is not particularly exposed. A small amino acid was found to be advantageous in this position. If a large amino acid, such as valine, is inserted in this position, it might collide with M93, and as a result, the structure may be affected. Changing the G112V mutation, selected during directed evolution, to an alanine (A) was found to be beneficial for preserving C5aR blocking activity in all clones carrying the G112V mutation. Interestingly, three of the seven top clones (variants 335, 338 and 377) were the same as clones found during directed evolution, but with a substitution to A in position 112 instead of V.
Among the final seven clones, 4 out of 12 lysines are mutated to arginines. Arginine substitutions of the lysines in positions 92 and 105 are found in three of the clones and in position 100 in four of the clones. There may be several explanations to why the four lysines have been substituted by arginines. The substitution from lysine to arginine can arise from only one base change, and arginine has many properties similar to lysine, while several of the other amino acids, possible to achieve through one base change, are more different from lysine and therefore fit onto the surface of the protein with more difficulty. Arginines might stabilize the protein and are generally common in binding surfaces. In the CHIPS variants, arginines may contribute to the preserved C5aR binding.
The approach to combine random mutagenesis or directed evolution with computational/rational design has also been successfully applied by others (Buskirk et al., 2004) . For example, mutagenesis can first be utilized to provide information on residues important to mutate. This way, mutagenesis can be directed from a randomized point of view instead of being based on rational choices (Lingen et al., 2002) .
Our results demonstrate that epitopes for human IgG can be efficiently reduced in a protein of bacterial origin by the use of directed evolution and computational/rational design. The removal of antibody epitopes is relevant in several disciplines within immunology. In allergy research, IgE epitopes are removed to create hypoallergenic allergen derivatives to be used as candidate vaccines (Vrtala et al., 2004; Linhart et al., 2008; Mothes-Luksch et al., 2008; Szalai et al., 2008) . This work has been performed mainly by epitope mapping and subsequent genetic engineering or by the design of mosaic proteins or hybrid molecules, but there are also studies where hypoallergens have been created by the use of directed evolution. In a recent study (Gafvelin et al., 2007) , directed evolution by multi-gene recombination to three group 2 mite allergen genes generated hypoallergen candidates with reduced IgE reactivity and preserved T-cell reactivity.
In conclusion, by the use of directed evolution, computational analysis and rational design, we have generated new CHIPS molecules with decreased interaction with preexisting specific human IgG, without affecting the interaction between CHIPS and the C5aR to a high extent. This work has resulted in CHIPS variants that are more promising potential drug candidates than the wt CHIPS 1 -121 protein, because they will potentially not form complexes with preexisting human IgG, and thereby be better tolerated and function more efficiently as C5aR antagonists than the wt CHIPS 1 -121 protein.
